Iptacopan monotherapy in patients with paroxysmal nocturnal hemoglobinuria: a 2-cohort open-label proof-of-concept study.

Jang, Jun Ho; Wong, Lily; Ko, Bor-Sheng; Yoon, Sung-Soo; Li, Katie; Baltcheva, Irina; Nidamarthy, Prasanna Kumar; Chawla, Raghav; Junge, Guido; Yap, Eng Soo

Jang, Jun Ho; Wong, Lily; Ko, Bor-Sheng; Yoon, Sung-Soo; Li, Katie; Baltcheva, Irina; Nidamarthy, Prasanna Kumar; Chawla, Raghav; Junge, Guido; Yap, Eng Soo.

Afiliação

Jang JH; Sungkyunkwan University School of Medicine, Samsung Medical Center, Seoul, South Korea.
Wong L; Hematology Unit, Queen Elizabeth Hospital, Kota Kinabalu, Malaysia.
Ko BS; Department of Internal Medicine, and.
Yoon SS; Department of Hematological Oncology, National Taiwan University Cancer Center, Taipei, Taiwan.
Li K; Department of Internal Medicine, Seoul National University Hospital, Seoul, South Korea.
Baltcheva I; Clinical Sciences and Innovation, Novartis Institutes for BioMedical Research, Shanghai, China.
Nidamarthy PK; Pharmacometrics, Novartis Pharma AG, Basel, Switzerland.
Chawla R; Biostatistics & Pharmacometrics, Novartis Healthcare Private Limited, Hyderabad, India.
Junge G; Translational Medicine, Novartis Institutes for BioMedical Research, Basel, Switzerland; and.
Yap ES; Translational Medicine, Novartis Institutes for BioMedical Research, Basel, Switzerland; and.

Blood Adv ; 6(15): 4450-4460, 2022 08 09.

Article em En | MEDLINE | ID: mdl-35561315

Assuntos

Hemoglobinúria Paroxística; Transfusão de Sangue; Estudos de Coortes; Hemólise; Humanos

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Hemoglobinúria Paroxística Tipo de estudo: Clinical_trials / Etiology_studies / Incidence_studies / Observational_studies / Risk_factors_studies Limite: Humans Idioma: En Ano de publicação: 2022 Tipo de documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google